Status:
UNKNOWN
Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?
Lead Sponsor:
Methodist Health System
Conditions:
MRSA
Eligibility:
All Genders
18-100 years
Brief Summary
Vancomycin, a glycopeptide antibiotic, is commonly prescribed as initial therapy for hospitalized patients due to its broad gram-positive coverage. Vancomycin is used for the treatment and prevention ...
Detailed Description
Vancomycin, a glycopeptide antibiotic, is commonly prescribed as initial therapy for hospitalized patients due to its broad gram-positive coverage. Vancomycin is used for the treatment and prevention ...
Eligibility Criteria
Inclusion
- Patients hospitalized from June 2020- January 2021.
- 18 years and older
- At least 1 vancomycin trough concentration drawn at steady state
- Organism with an MIC of 2 mg/L, if vancomycin was continued and in whom a steady state trough concentration was obtained
Exclusion
- Patients with end stage renal disease (on hemodialysis or peritoneal dialysis) or on continuous renal replacement therapy
Key Trial Info
Start Date :
April 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 8 2024
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT05395520
Start Date
April 8 2021
End Date
April 8 2024
Last Update
July 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203